407 related articles for article (PubMed ID: 16924165)
1. Obesity: new perspectives and pharmacotherapies.
Palamara KL; Mogul HR; Peterson SJ; Frishman WH
Cardiol Rev; 2006; 14(5):238-58. PubMed ID: 16924165
[TBL] [Abstract][Full Text] [Related]
2. Current and investigational antiobesity agents and obesity therapeutic treatment targets.
Bays HE
Obes Res; 2004 Aug; 12(8):1197-211. PubMed ID: 15340100
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological therapies for obesity.
Kaplan LM
Gastroenterol Clin North Am; 2005 Mar; 34(1):91-104. PubMed ID: 15823441
[TBL] [Abstract][Full Text] [Related]
4. Drug treatment of obesity in cardiovascular disease.
Charakida M; Finer N
Am J Cardiovasc Drugs; 2012 Apr; 12(2):93-104. PubMed ID: 22292446
[TBL] [Abstract][Full Text] [Related]
5. Drug therapy for obesity.
Dickerson LM; Carek PJ
Am Fam Physician; 2000 Apr; 61(7):2131-8, 2143. PubMed ID: 10779254
[TBL] [Abstract][Full Text] [Related]
6. New perspectives on diagnosis and treatment of obesity.
Mogul HR; Rau J; Weinstein BI; Zhang S; Peterson SJ
Heart Dis; 1999; 1(5):295-304. PubMed ID: 11720637
[TBL] [Abstract][Full Text] [Related]
7. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
Lee M; Aronne LJ
Am J Cardiol; 2007 Feb; 99(4A):68B-79B. PubMed ID: 17307059
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular consequences of obesity.
Okerberg K; Hamilton Dougherty A
Curr Womens Health Rep; 2003 Apr; 3(2):110-5. PubMed ID: 12628080
[TBL] [Abstract][Full Text] [Related]
9. Obesity pharmacotherapy from a regulatory perspective: overview and key challenges.
Hutchinson NI; Ryder SW
Clin Pharmacol Ther; 2007 May; 81(5):756-60. PubMed ID: 17392723
[TBL] [Abstract][Full Text] [Related]
10. Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends?
Ballantyne CM
Crit Pathw Cardiol; 2007 Jun; 6(2):41-5. PubMed ID: 17667863
[TBL] [Abstract][Full Text] [Related]
11. Obesity and cardiovascular risk: the new public health problem of worldwide proportions.
Scaglione R; Argano C; Di Chiara T; Licata G
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):203-12. PubMed ID: 15151469
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic options for modifying cardiometabolic risk factors.
Aronne LJ
Am J Med; 2007 Mar; 120(3 Suppl 1):S26-34. PubMed ID: 17320519
[TBL] [Abstract][Full Text] [Related]
13. Anti-obesity drugs: a review about their effects and their safety.
Derosa G; Maffioli P
Expert Opin Drug Saf; 2012 May; 11(3):459-71. PubMed ID: 22439841
[TBL] [Abstract][Full Text] [Related]
14. Management issues in the metabolic syndrome.
Deedwania PC; Gupta R
J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
[TBL] [Abstract][Full Text] [Related]
15. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.
Jensen MD
Obesity (Silver Spring); 2006 Jun; 14 Suppl 3():143S-149S. PubMed ID: 16931496
[TBL] [Abstract][Full Text] [Related]
16. Obesity - an epidemic of the twenty-first century: an update for psychiatrists.
Holt RI
J Psychopharmacol; 2005 Nov; 19(6 Suppl):6-15. PubMed ID: 16280333
[TBL] [Abstract][Full Text] [Related]
17. Challenges and strategies in managing cardiometabolic risk.
Repas TB
J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S4-11. PubMed ID: 17784529
[TBL] [Abstract][Full Text] [Related]
18. An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
Dastjerdi MS; Kazemi F; Najafian A; Mohammady M; Aminorroaya A; Amini M
Int J Obes (Lond); 2007 Apr; 31(4):713-7. PubMed ID: 16969361
[TBL] [Abstract][Full Text] [Related]
19. [A practicing physician's view on obesity].
Juhász A; Katona E; Csongrádi E; Paragh G
Orv Hetil; 2006 Apr; 147(13):579-90. PubMed ID: 16623440
[TBL] [Abstract][Full Text] [Related]
20. Treatment modalities of obesity: what fits whom?
Hainer V; Toplak H; Mitrakou A
Diabetes Care; 2008 Feb; 31 Suppl 2():S269-77. PubMed ID: 18227496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
